Patents by Inventor Laetitia COMPS-AGRAR

Laetitia COMPS-AGRAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20240092887
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Application
    Filed: August 2, 2023
    Publication date: March 21, 2024
    Inventors: Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Tiffany WONG, Jia WU, Hongkang XI, Jack BEVERS, III, Hiu Nam CHAN, Laetitia COMPS-AGRAR, Racquel CORPUZ
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 11760797
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20210340253
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20210332132
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20210284725
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Application
    Filed: March 12, 2021
    Publication date: September 16, 2021
    Inventors: Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Tiffany WONG, Jiansheng WU, Hongkang XI, Jack BEVERS, III, Joyce CHAN, Laetitia COMPS-AGRAR, Racquel CORPUZ
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20200399366
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: March 13, 2020
    Publication date: December 24, 2020
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
    Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 9873740
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170044256
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170037127
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20150216970
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 16, 2014
    Publication date: August 6, 2015
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR